Search results
Showing 6316 to 6330 of 8980 results
Recommendation ID NG25/1 Question Prophylactic cervical cerclage compared with prophylactic vaginal progesterone for preventing preterm
Recommendation ID NG25/4 Question Magnesium sulfate for neuroprotection: bolus plus infusion compared with bolus alone:- What is the clinical
Recommendation ID NG25/3 Question Effectiveness of 'rescue' cerclage:- What is the clinical effectiveness of 'rescue' cerclage in improving
Recommendation ID NG122/1 Question What is the effectiveness and cost effectiveness of immunotherapy in people with stage IIIA-N2 non-small-cell
Recommendation ID NG25/2 Question Identifying infection in women with preterm prelabour rupture of membranes (P-PROM):- What is the diagnostic
Recommendation ID IPG652/1 Question Current evidence on the safety and efficacy of bronchoscopic thermal vapour ablation for upper-lobe
Recommendation ID NG134/4 Question What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of a brief
Recommendation ID NG85/2 Question Cachexia interventions: - A cohort study followed by phase II and III studies should be undertaken in
Injection for more than a million people to help prevent heart attacks and strokes recommended
People who have had a heart attack, stroke, or serious circulation problem in their legs, and who also carry excess weight, can now be offered a weekly injection to help protect them from a further life-threatening event, NICE has said.
Endometriosis now has its own fertility pathway in NICE guidance
The updated fertility guideline includes a brand-new section specifically for those with endometriosis who are struggling to conceive.
MHRA-NICE pathway opens for business – everything you need to know to get started
Learn how the MHRA and NICE are getting medicines to patients 3 to 6 months sooner by delivering same time decisions on licensing and value.
Sophie Cooper, senior scientific adviser in NICE’s science policy team, explains the importance of the recently published EQ-5D-5L value set and how it has the potential to help us decide if new treatments offer good value for money for the NHS.
'Trojan horse' treatment recommended for people with multiple myeloma
Around 1,600 people a year in England with multiple myeloma are set to benefit from a new treatment option after we recommended belantamab mafodotin (also known as Blenrep and made by GSK).
Home News Podcasts Backing the healthtech that changes lives Podcasts 31 March 2026 Listen About this episode When the right technology reaches
New take at home drug recommended for people with chronic lymphocytic leukaemia
Our latest draft guidance recommends pirtobrutinib, a new take at home tablet, that could give patients greater choice and reduce the need for frequent hospital visits.